- Frontage Laboratories has completed the acquisition of Teddy Clinical Research Laboratory (Shanghai), Ltd., expanding its laboratory services capabilities in China and the Asia-Pacific region.
- Teddy Lab has supported more than 1,500 clinical trials and contributed to 50 approved drugs, bringing established clinical laboratory expertise to Frontage’s service platform.
Frontage Laboratories has completed the acquisition of Teddy Clinical Research Laboratory (Shanghai), Ltd., a clinical research laboratory service provider based in China. The transaction is intended to expand Frontage’s laboratory service capabilities and strengthen its operational footprint in China and the broader Asia-Pacific region.
Teddy Lab has supported more than 1,500 clinical trials across multiple therapeutic areas. The laboratory operates under Good Clinical Practice (GCP)-compliant processes and maintains several internationally recognized quality certifications, including CAP accreditation and NGSP Level 1 certification. The facility is also qualified as a Class II Unsealed Radioactive Material Workplace, supporting regulated laboratory testing services for pharmaceutical and biotechnology companies.
Through the acquisition, Frontage expands its central laboratory network in China, which the company expects will support growing demand for both domestic clinical trials and multi-regional clinical trials. Teddy Lab’s capabilities will be integrated with Frontage’s broader service platform, which includes bioanalytical services, DMPK studies, safety and toxicology testing, CMC support, and clinical trial services.
Frontage stated that the integration is intended to enhance its ability to provide a broader range of drug development services to pharmaceutical and biotechnology clients. The company expects the expanded infrastructure and scientific capabilities to support increasing demand for global clinical research programs.
The acquisition forms part of Frontage’s strategy to strengthen its role in the clinical research services market by expanding global laboratory capacity and supporting pharmaceutical and biotechnology partners conducting clinical trials and drug development programs.
